BR112023000187A2 - Peptídeos brk e métodos de uso - Google Patents

Peptídeos brk e métodos de uso

Info

Publication number
BR112023000187A2
BR112023000187A2 BR112023000187A BR112023000187A BR112023000187A2 BR 112023000187 A2 BR112023000187 A2 BR 112023000187A2 BR 112023000187 A BR112023000187 A BR 112023000187A BR 112023000187 A BR112023000187 A BR 112023000187A BR 112023000187 A2 BR112023000187 A2 BR 112023000187A2
Authority
BR
Brazil
Prior art keywords
peptides
brk
methods
isolated
p27kip1
Prior art date
Application number
BR112023000187A
Other languages
English (en)
Inventor
Bridon Dominique
Original Assignee
Concarlo Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concarlo Holdings Llc filed Critical Concarlo Holdings Llc
Publication of BR112023000187A2 publication Critical patent/BR112023000187A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/101—Plasmid DNA for bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

PEPTÍDEOS BRK E MÉTODOS DE USO. A presente invenção refere-se a peptídeos BRK isolados truncados e peptídeos funcionais dos mesmos que inibem a fosforilação de p27Kip1 e a atividade de quinase resultante de CDK2 e CDK4; e a composições farmacêuticas dos mesmos. A invenção refere-se ainda ao uso dos peptídeos isolados em métodos de tratamento de câncer em indivíduo em necessidade do mesmo.
BR112023000187A 2020-07-06 2021-07-06 Peptídeos brk e métodos de uso BR112023000187A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063048489P 2020-07-06 2020-07-06
PCT/US2021/040536 WO2022010914A2 (en) 2020-07-06 2021-07-06 Brk peptides and methods of use

Publications (1)

Publication Number Publication Date
BR112023000187A2 true BR112023000187A2 (pt) 2023-01-31

Family

ID=79552706

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023000187A BR112023000187A2 (pt) 2020-07-06 2021-07-06 Peptídeos brk e métodos de uso

Country Status (10)

Country Link
US (1) US20230293643A1 (pt)
EP (1) EP4175659A4 (pt)
JP (1) JP2023533036A (pt)
KR (1) KR20230136910A (pt)
CN (1) CN115996745A (pt)
AU (1) AU2021303405A1 (pt)
BR (1) BR112023000187A2 (pt)
CA (1) CA3184955A1 (pt)
IL (1) IL299654A (pt)
WO (1) WO2022010914A2 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117589905B (zh) * 2023-11-21 2024-04-26 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种可作为胃癌诊断标志物的脂质代谢物组合及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
WO2015175965A1 (en) * 2014-05-15 2015-11-19 The Research Foundation For Suny Compositions targeting the interaction domain between p27kip1 and brk and methods of use thereof
CN109069485A (zh) * 2016-02-23 2018-12-21 纽约州立大学研究基金会 P27酪氨酸磷酸化作为cdk4活性的标志物及其使用方法

Also Published As

Publication number Publication date
WO2022010914A3 (en) 2022-03-10
CN115996745A (zh) 2023-04-21
KR20230136910A (ko) 2023-09-27
WO2022010914A2 (en) 2022-01-13
EP4175659A2 (en) 2023-05-10
US20230293643A1 (en) 2023-09-21
IL299654A (en) 2023-03-01
AU2021303405A1 (en) 2023-02-23
CA3184955A1 (en) 2022-01-13
EP4175659A4 (en) 2024-07-24
JP2023533036A (ja) 2023-08-01

Similar Documents

Publication Publication Date Title
BR112015011171A2 (pt) compostos de pirrolopirimidina como inibidores da quinase
BR112014018728A8 (pt) Compostos de purinonas como inibidores de quinase
BR112019018685A8 (pt) Anticorpos, composição farmacêutica, kit, usos de um anticorpo e método in vitro de identificação ou seleção de um anticorpo
BR112022002698A2 (pt) Compostos de imidazolil pirimidinilamina como inibidores de cdk2
Kraus et al. Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations
BR112018071585A2 (pt) formulações de um inibidor de lsd1
BR112016006978A2 (pt) inibidores de tirosina quinase de bruton
CL2022000922A1 (es) Aminas bicíclicas como inhibidores de la cdk2.
BR112018002427A8 (pt) Uso de alvocidib e de azacitidina ou decitabina para tratar câncer e kit e composição farmacêutica contendo as ditas substâncias
BR112022009631A2 (pt) Combinações de inibidores de dgk e antagonistas do ponto de checagem
BR112017026467A2 (pt) uso de exossomos para o tratamento de doença
BR112018002130A2 (pt) anticorpo de domínio único e proteínas derivadas respectivas contra um ligante de morte programada (pdl1)
BR112017019343A2 (pt) uso de composições contendo peptídeo inibidor de mk2 para tratamento de câncer de pulmão de células não pequenas com as mesmas
MX2019013735A (es) Antimitoscinas: inhibidores especificos de la biogenesis mitocondrial para erradicar celulas madre cancerosas.
Ayyagari et al. Bithionol inhibits ovarian cancer cell growth in vitro-studies on mechanism (s) of action
BRPI0622054B8 (pt) composto e composição farmacêutica
BR112015001690A2 (pt) mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk)
Rahman et al. Hydrogen peroxide/ceramide/Akt signaling axis play a critical role in the antileukemic potential of sanguinarine
BR112018013084A2 (pt) tratamentos de combinação compreendendo a administração de imidazopirazinonas
BR112017025698A2 (pt) composições e métodos para inibir a expressão do gene de hif2alfa
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112023002951A2 (pt) Compostos de fosfolipídio e usos destes
BR112023000187A2 (pt) Peptídeos brk e métodos de uso
BR112019002458A2 (pt) composições e métodos para tratar câncer com depleção de arginina e agentes imuno-oncológicos
BR112015022982A2 (pt) inibidores macrocíclicos de rip2 quinase